Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
24 results
D2.545 - Perception of adult patients in an allergy clinic after using Scribe artificial intelligence, our experience
D2.546 - Ethical Impact of Generative AI in Clinical Practice for Asthma and Allergy
D2.547 - The Transparent and Credible AI for Clinical Protocols
D2.548 - Expert Evaluation of Dialogue Quality and Clinical Reasoning in a Hybrid Multilingual LLM–Algorithm Allergy Decision-Support System: A Pilot Study of 34 Real-World Cases
D3.157 - Clinical characteristics and associated factors of persistent asthma in preschool children with wheezing in a tropical region
D3.158 - Dupilumab Response in a Patient with Severe Asthma Refractory to Anti-IL5 Therapy: A Case Report
D3.165 - Phase 1 study of CDX-622, a bispecific antibody targeting TSLP and mast cells via stem cell factor
D3.153 - Add-on Dupilumab therapy significantly reduces severe asthma exacerbations and emergency visits in patients with severe persistent asthma requiring oral corticosteroids for maintenance therapy: our experience in Réunion Island
D3.154 - Trends in Bronchial Asthma Incidence in Crimea: Analysis from 2017-2024 with Age-Specific Insights
D3.155 - Th2–Th17 immune shift following dupilumab therapy
D3.156 - Pulmonary embolism in a young asthma patient
D3.159 - Early Bronchodilator Response in Asthma: When Is Testing Really Necessary?
D3.160 - Study of the allergic sensitization profile in asthmatic patients consulting at ignace deen university hospital, conakry
D3.161 - Efficacy and Safety of Ciclesonide in Achieving Asthma Control: Results of an Observational Multicenter Study in Real-World Clinical Practice
D3.164 - Early and Sustained Effect of Zumilokibart (APG777) in Atopic Dermatitis and Asthma: 16-Week Results from the Phase 2 APEX Study in Moderate-to-Severe AD and a Phase 1b Study in Mild-to-Moderate Asthma
D3.232 - The AhR agonist tapinarof suppresses human skin inflammation by inducing metabolic reprogramming and reducing production of mitochondrial pro-inflammatory DAMPs
D3.231 - Gut Microbiome Dysbiosis in Antihistamine-Refractory Chronic Spontaneous Urticaria and Its Association with Disease Characteristics- A Cross-Sectional Case–Control Analysis
D3.233 - Polypharmacy-Associated Lichenoid Eruption Simulating Keratosis Lichenoides Chronica
D3.234 - Successful Use of Ritlecitinib in Long-Standing Alopecia Areata with Previous JAK Inhibitor Failure
D3.235 - Trends in Sensitization to Preservatives and Epoxy Resins among occupationally exposed workers: A 31-Year Patch Test analysis from Tunisia
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download